12 results match your criteria: "The University of Melbourne and St Vincent's Hospital[Affiliation]"
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
January 2024
From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia "Seràgnoli," and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.).
Background: Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of transplantation-eligible patients with newly diagnosed multiple myeloma is needed.
Methods: In this phase 3 trial, we randomly assigned 709 transplantation-eligible patients with newly diagnosed multiple myeloma to receive either subcutaneous daratumumab combined with VRd induction and consolidation therapy and with lenalidomide maintenance therapy (D-VRd group) or VRd induction and consolidation therapy and lenalidomide maintenance therapy alone (VRd group).
Exercise interventions to reduce anxiety in mid-life and late-life anxiety disorders and subthreshold anxiety disorder: a systematic review.
Ther Adv Psychopharmacol
July 2022
Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia.
Background: Anxiety disorders are highly prevalent and cause significant distress, disability, and cost. Medication adverse effects and interactions increase in mid-life and late-life, highlighting the need for effective non-pharmacological interventions.
Objectives: We aimed to evaluate the extent of evidence supporting exercise interventions for anxiety and subthreshold anxiety disorders in mid-life and late-life.
Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.
Lancet Respir Med
April 2021
Department of Critical Care Medicine, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia.
Article Synopsis
- This study investigates the effects of nebulised heparin on lung injury in mechanically ventilated patients at risk for acute respiratory distress syndrome (ARDS), addressing the long-term impairments survivors may face.
- Conducted as a multicenter, double-blind trial, it randomized adult intensive care patients to receive either nebulised heparin or a placebo while on invasive ventilation.
- The primary goal was to assess whether heparin could improve physical function at 60 days post-treatment, measured by the Short Form 36 Health Survey Score.
Psychiatrists' perceptions of medication adherence among patients with schizophrenia: An international survey.
Schizophr Res
September 2019
Department of Psychiatry, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 75-59 263rd Street Glen Oaks, New York 11004-1150, United States.
The impact of older age on patient outcomes following primary total knee arthroplasty.
Bone Joint J
November 2018
The University of Melbourne and St. Vincent's Hospital Melbourne, Melbourne, Australia.
Aims: As the population ages, there is projected to be an increase in the level of demand for total knee arthroplasty (TKA) in octogenarians. We aimed to explore whether those aged ≥ 80 years achieved similar improvements in physical function to younger patients while also comparing the rates of length of stay (LOS), discharge to rehabilitation, postoperative complications, and mortality following TKA in older and younger patients.
Patients And Methods: Patients from one institution who underwent primary elective TKA between 1 January 2006 and 31 December 2014 were dichotomized into those ≥ 80 years old (n = 359) and those < 80 years old (n = 2479) for comparison.
Revising , Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project.
Aust N Z J Psychiatry
December 2018
CADE Clinic, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, NSW, Australia.
Objective: To derive new criteria sets for defining manic and hypomanic episodes (and thus for defining the bipolar I and II disorders), an international Task Force was assembled and termed AREDOC reflecting its role of Assessment, Revision and Evaluation of DSM and other Operational Criteria. This paper reports on the first phase of its deliberations and interim criteria recommendations.
Method: The first stage of the process consisted of reviewing , and recent International Classification of Diseases criteria, identifying their limitations and generating modified criteria sets for further in-depth consideration.
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.
Am J Psychiatry
March 2017
From King's College London, Institute of Psychiatry, Psychology, and Neuroscience; MRC Clinical Sciences Centre; Institute of Clinical Sciences, Imperial College, and Hammersmith Hospital London; the Department of Psychiatry, University of Toronto, and the Centre for Addiction and Mental Health, Toronto; the Section of Psychiatry and Treatment Resistant Psychosis and the Laboratory of Translational Psychiatry, School of Medicine of Naples Federico II, Naples; the Departments of Psychiatry and Neuroscience, Erasmus Medical Center, and Antes Mental Health Care, Rotterdam, the Netherlands; the Feinstein Institute for Medical Research, Psychiatry Research, Zucker Hillside Hospital, Hofstra Northwell School of Medicine; the Division of Psychiatry, University College London; Laboratorio Interdisciplinar de Neurociencia Clinica, Universidade Federal de São Paulo, São Paulo; the Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore; the University of Melbourne and St. Vincent's Hospital, Sydney; the Department of Psychiatry and Behavioral Sciences, New York Medical College, New York; the Department of Psychiatry, Tel Aviv University, Tel Aviv; the Division of Health Sciences, School of Psychology and Mental Health, Faculty of Biology, Medicine, and Health, University of Manchester, and the Manchester Academic Health Science Centre, Manchester Mental Health and Social Care NHS Trust, Manchester; the Department of Psychiatry, University of Alberta, Edmonton; the Center for Neuropsychiatric Schizophrenia Research and the Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Mental Health Center Glostrup, University of Copenhagen, Copenhagen; the Department of Psychiatry, University of São Paulo Medical School, São Paulo; the Department of Psychiatry, University of Munich, Munich; the Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Programa de Esquizofrenia and Laboratorio Interdisciplinar de Neurociencia Clinica, Universidade Federal de São Paulo, São Paulo; the National Psychosis Service, South London and Maudsley NHS Foundation Trust; the Neuroscience and Behavior Department, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo; the Department of Psychiatry, University of British Columbia; Lundbeck LLC, Deerfield, Ill.; University Department of Psychiatry, Royal Edinburgh Hospital, Edinburgh; the Department of General Psychiatry, Institute of Mental Health, Singapore; the Deparment of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Heidelberg; the Brain and Mind Centre, University of Sydney, Sydney; the School of Pharmacy, University of Auckland, Auckland, New Zealand; the Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago; the Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich; the Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo; the Department of Psychiatry, Melbourne Neuropsychiatry Centre, University of Melbourne, and Melbourne Health, Victoria; the Schizophrenia Division, Centre for Addiction and Mental Health, Toronto; the Centre for Mental Health, Swinburne University, the Monash Alfred Psychiatry Research Centre, and the Department of Psychiatry, St. Vincent's Hospital Melbourne, Sydney; the School of Pharmacy, University of Otago, Otago, New Zealand; COS and Associates Ltd., Hong Kong; the Department of Neuropsychiatry, Keio University School of Medicine, Keio, Japan; the Department of Neuroscience, University Medical Center Utrecht, Utrecht, the Netherlands; Swinburne University and Monash Alfred Psychiatry Research Centre, Brain and Psychological Sciences Research Centre, Melbourne; the Istanbul Faculty of Medicine, Istanbul University, Istanbul; Clinical Research and Early Development, F. Hoffmann -La Roche Ltd., Basel, Switzerland; the Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, and the MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff; Psychiatry Research, Zucker Hillside Hospital, Long Island Jewish Medical Center, Hofstra Northwell School of Medicine, and the Feinstein Institute for Medical Research, New York.
Objective: Research and clinical translation in schizophrenia is limited by inconsistent definitions of treatment resistance and response. To address this issue, the authors evaluated current approaches and then developed consensus criteria and guidelines.
Method: A systematic review of randomized antipsychotic clinical trials in treatment-resistant schizophrenia was performed, and definitions of treatment resistance were extracted.
Low-molecular-weight heparin biosimilars: potential implications for clinical practice. Australian Low-Molecular-Weight Heparin Biosimilar Working Group (ALBW).
Intern Med J
May 2014
Department of Medicine and Haematology, The University of Melbourne and St Vincent's Hospital, Melbourne, Victoria, Australia.
A working group of clinicians and scientists was formed to review the clinical considerations for use of low-molecular-weight heparin (LMWH) biosimilars. LMWH are biological molecules of significant complexity; the full complexity of chemical structure is still to be elucidated. LMWH biosimilars are products that are biologically similar to their reference product and rely on clinical data from a reference product to establish safety and efficacy.
View Article and Find Full Text PDFSupporting family caregivers of hospitalised palliative care patients: a psychoeducational group intervention.
BMJ Support Palliat Care
June 2012
Centre for Palliative Care, The University of Melbourne and St Vincent's Hospital, Melbourne, Australia.
Background: Many family caregivers of palliative care patients experience poor health and have other unmet needs, requiring health professionals' support. However, there are few evidence-based supportive interventions to address these issues.
Purpose: The purpose of this project was to undertake preliminary testing of a psychoeducational group education programme, delivered in an in-patient setting, designed to prepare family caregivers for the role of supporting a relative currently receiving hospital-based palliative care.
Background: Family caregivers of patients requiring palliative care commonly experience physical, social, and psychological burdens. Although family caregivers are acknowledged as valid service recipients of palliative care, many have unmet needs, and systematic reviews have shown there are limited evidence-based supportive interventions.
Objectives: This study aimed to develop and pilot test a psycho-educational group education program delivered in the inpatient specialist palliative care setting and designed to prepare primary family caregivers for the role of supporting a relative receiving hospital-based palliative care.
Economic burden of obesity in primary total knee arthroplasty.
Arthritis Care Res (Hoboken)
October 2011
The University of Melbourne and St. Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
Objective: To compare the hospital inpatient costs between nonobese and obese patients and estimate the economic burden of obesity in primary total knee arthroplasty (TKA).
Methods: A cost identification study was conducted in a consecutive cohort of 530 patients who underwent TKA between 2006 and 2007 at a university-affiliated tertiary referral center in Melbourne, Australia. Total hospital inpatient costs incurred at the study institution associated with the index surgery and subsequent related emergency presentations and readmissions during the episode of care were captured.
Visualisation and stereological assessment of blood and lymphatic vessels.
Histol Histopathol
June 2011
Bernard O'Brien Institute of Microsurgery and the University of Melbourne and St Vincent's Hospital Department of Surgery, 42 Fitzroy Street, Fitzroy, Victoria 3065, Australia.
The physiological processes involved in tissue development and regeneration also include the parallel formation of blood and lymphatic vessel circulations which involves their growth, maturation and remodelling. Both vascular systems are also frequently involved in the development and progression of pathological conditions in tissues and organs. The blood vascular system circulates oxygenated blood and nutrients at appropriate physiological levels for tissue survival, and efficiently removes all waste products including carbon dioxide.
View Article and Find Full Text PDF